Back to results
US 10,377,832 B2Granted
Modified glycoproteins
AssigneeMomenta Pharmaceuticals, Inc.
InventorsNathaniel Washburn, James Meador, III, Carlos J. Bosques, Dorota A. Bulik, Naveen Bhatnagar, Julia Brown, Lynn Markowitz, Sathya Prabbhakar
Life of this patent
Estimating the term…
Abstract
Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
Claims15
A method of producing a preparation of recombinant glycoprotein, the method comprising:
- expressing in a cell a recombinant glycoprotein comprising a modified amino acid sequence of a reference glycoprotein, the reference glycoprotein comprising an immunoglobulin Fc region or Fc fragment,
- wherein the recombinant glycoprotein comprises an Fc region or Fc fragment comprising two amino acid substitutions relative to the Fc region or Fc fragment of the reference glycoprotein, wherein the two amino acid substitutions are F241A/F243A, F241A/K246A, F241A/T260A, F241A/R301A, F243A/K246A, F243A/T260A, F243A/R301A, K246A/T260A, K246A/R301A, or T260A/R301A, as numbered according to the EU numbering index of Kabat;
- and
- isolating the recombinant glycoprotein, thereby producing the preparation of recombinant glycoprotein, wherein the preparation has an increased level of one or more of sialylated glycans, fucosylated glycans, and N-acetylglucosamine glycans, relative to a preparation of the reference glycoprotein.
1 more element
Dependencies are inferred from the claim text.